These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24579720)

  • 1. Novel monoclonal antibodies for therapy of multiple sclerosis.
    Knier B; Hemmer B; Korn T
    Expert Opin Biol Ther; 2014 Apr; 14(4):503-13. PubMed ID: 24579720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.
    D'Amico E; Messina S; Caserta C; Patti F
    Expert Opin Drug Saf; 2015 Jul; 14(7):1157-68. PubMed ID: 25826609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies in the treatment of multiple sclerosis.
    Di Pauli F; Berger T; Reindl M
    Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
    Deiß A; Brecht I; Haarmann A; Buttmann M
    Expert Rev Neurother; 2013 Mar; 13(3):313-35. PubMed ID: 23448220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating multiple sclerosis with monoclonal antibodies.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in neuroinflammatory diseases.
    Klotz L; Wiendl H
    Expert Opin Biol Ther; 2013 Jun; 13(6):831-46. PubMed ID: 23521026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying agents in multiple sclerosis.
    O'Connor PW; Oh J
    Handb Clin Neurol; 2014; 122():465-501. PubMed ID: 24507532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Antibodies for Multiple Sclerosis: An Update.
    Graf J; Aktas O; Rejdak K; Hartung HP
    BioDrugs; 2019 Feb; 33(1):61-78. PubMed ID: 30604390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current evaluation of alemtuzumab in multiple sclerosis.
    Coyle PK
    Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal antibodies for the treatment of multiple sclerosis].
    Sánchez-Seco VG; Casanova Peño I; Arroyo González R
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():30-4. PubMed ID: 25732947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
    Trebst C; Voss E; Skripuletz T; Stangel M
    Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging monoclonal antibody therapies for multiple sclerosis.
    Cree B
    Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
    Keeley KA; Rivey MP; Allington DR
    Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab and multiple sclerosis: therapeutic application.
    Minagar A; Alexander JS; Sahraian MA; Zivadinov R
    Expert Opin Biol Ther; 2010 Mar; 10(3):421-9. PubMed ID: 20095876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
    Buttmann M
    Expert Rev Neurother; 2010 May; 10(5):791-809. PubMed ID: 20420497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S; Weinstock-Guttman B
    Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
    Ancau M; Berthele A; Hemmer B
    Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
    Gasperini C; Haggiag S; Ruggieri S
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.